Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 9/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | PDE1A | P54750 | 2/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.34 |
| ▸ | PDE5A | O76074 | 2/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.34 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10275806 | 0.84 | XDH (0.42) | XDHMEN1KMT2APTGS1PTGS2 | |
| SCHEMBL10313639 | 0.78 | PDE5A (0.48) | MEN1KMT2APDE5A | |
| SCHEMBL10313632 | 0.77 | XDH (0.47) | XDHMEN1KMT2A | |
| SCHEMBL10313630 | 0.77 | PI4KA (0.40) | XDHPTGS1PTGS2 | |
| SCHEMBL10313636 | 0.75 | MAPK14 (0.36) | PTGS1PTGS2 | |
| SCHEMBL10313616 | 0.63 | PI4KA (0.32) | — | |
| SCHEMBL10275396 | 0.61 | PDE5A (0.48) | MEN1KMT2APDE5A | |
| SCHEMBL10276251 | 0.60 | PI4KA (0.40) | PTGS1PTGS2 | |
| SCHEMBL10276398 | 0.60 | XDH (0.47) | XDHMEN1KMT2A | |
| SCHEMBL3310025 | 0.59 | XDH (0.76) | XDHMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | XDH 8/4885MEN1 4229/4885KMT2A 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.